Learn if You Have a Claim Against Pfizer, Inc. (maker of Neurontin)

Off-Label Use of Neurontin May Be Dangerous Kahn Gauthier Swick is investigating possible legal actions against drug giant Pfizer, Inc., the manufacturer of the prescription drug Neurontin (gabapentin), to recover for harm suffered by patients who have been prescribed Neurontin.
Claimant Information

Are you submitting this information on behalf of yourself?	Yes No
Are you submitting this information on behalf of a family member?	Yes No
If yes, please provide: Name
Age
Relationship
Were you prescribed Neurontin for any of the below listed ailments?

Bipolar Disorder	Yes No
Pain Syndromes, Peripheral Neuropathy, and Diabetic Neuropathy	Yes No
Treatment of Epilepsy Alone (as monotherapy)	Yes No
Reflex Sympathetic Dystrophy (RSD)	Yes No
Attention Deficit Disorder (ADD)	Yes No
Restless Leg Syndrome (RLS)	Yes No
Trigeminal Neuralgia	Yes No
Essential Tremor and Periodic Limb Movement	Yes No
Migraine	Yes No
Drug and Alcohol Withdrawal Seizures	Yes No
Other	Yes No
Neurontin Use

Please list your prescription information. Include; prescription date, pharmacy name and address, number of pills, dosage, and number of days.
Was there ever a suicide or suicide attempt? Please explain.
Are you still taking Neurontin?	Yes No
Are you presently covered by health insurance?	Yes No
Have you previously retained an attorney to represent you in this matter?	Yes No

Personal Information

First Name

Last Name

Street / Apt /

City, State Zip

Home Phone & Evening Phone (Same) . . & . .

E-Mail Address

Confirm E-Mail

Date Issue/Problem

Terms & Conditions
I acknowledge that I have read and understand and agree to the following legal policies.

Certain features of Lawcash.com require a login - please simply choose a password to continue.

Password

Confirm Password

I'd like to become a Lawcash.com member, receive a free class action ebook, and free class action and recall alerts. Billions of dollars are available each year and I'd like to claim my fair share from bad corporations.

Submit

Other Drugs / Medical Cases of Interest

Allos Therapeutics Accused of Finding an Experimental Group to Make RSR13 Anticancer Drug Look Good

Several class actions have been filed against biopharmaceutical research company Allos Therapeutics, Inc., (Nasdaq:ALTH) and certain of its officers and directors by stockholders who purchased the company's common stock between April 23, 2003, and April 29, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.

Drug Manafacturer Impax Laboratories Accused of Inflating Earnings Reports

A class action has been filed against drug manufacturer Impax Laboratories, Inc. (Nasdaq:IPXL) and certain of its officers and directors by stockholders who purchased the company’s common stock between May 5, 2004 and November 3, 2004. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company’s securities. The stockholders seek to recover compensatory damages for the loss of value of their stock.

Judge Ok's Class Action Against Arkansas Nursing Home Operator

Beverly Enterprises Inc. played hardball in two Arkansas courthouses, withholding and losing patient records and other information. One judge has threatened jail time for the company’s chief executive, and another judge granted a default judgment against the company for operating a "shell game."

Claimant Notification Begins in $65 Million Dollar Paxil Overpayment Case

A settlement valued at 65 Million dollars has been reached in the consolidated action concerning alleged efforts by drug manufacturer Smith Kline Beecham to delay or impede the release of generic versions of the antidepressant drug Paxil, in order to continue selling the name brand drug at higher cost. On November 18, 2004 court ordered notification of potential claimainst began. Notices will be mailed, and are scheduled to appear in newspapers and magazines all over the United States, leading up to a hearing on March 9, 2005, when the Court will consider whether to approve the settlement.

Stockholders Claim Dura Pharmaceuticals Misled Market

A class action has been filed against Dura Pharmaceuticals, Inc. (formerly Nasdaq: DURA) and certain of its officers and directors by stockholders who purchased the company's common stock between April 15, 1997, and February 24, 1998.

Women Covered by Regence Blue Shield Health Insurance Policies Want Access to All FDA-Approved Contraceptives

Women's rights advocates have been pressing ahead in the battle to provide women with parity in the healthcare field. A class action has been filed against Washington state healthcare insurance provider Regence Blue Shield on behalf of female policyholders who allege that they have been denied coverage for FDA-approved forms of contraception, in violation of state insurance and consumer protection laws.